Title
Simvastatin as an Augmentation Treatment for Treatment Resistant Depression: Randomized Controlled Trial.
A Multicentre 12-week Randomised, Double Blind, Placebo Controlled Trial of Simvastatin as Augmentation Treatment for Treatment-resistant Depression
Phase
Phase 3Lead Sponsor
Pakistan Institute of Living and LearningStudy Type
InterventionalStatus
Completed No Results PostedIndication/Condition
Treatment Resistant Depression Major Depressive DisorderIntervention/Treatment
Simvastatin 20 mg ...Study Participants
150In this double blind, randomized placebo controlled trial we aim to determine the efficacy of simvastatin as an add-on treatment for treatment resistant depression. We will recruit 150 people with treatment-resistant depression with the aim of determining whether the addition of simvastatin (20mg daily) to treatment as usual (TAU) for 12 weeks leads to an improvement in depressive symptom compared with placebo added to TAU.
Matched placebo added to TAU for 3 months
Participants will receive Simvastatin 20 mg added to TAU for 3 months
Participants will receive placebo added to TAU for 3 months
Inclusion Criteria: DSM-5 current major depressive episode Must currently be on an antidepressant and must have had a non-response to >2 oral antidepressant treatments in the current episode (including the one they are currently taking). Capacity to give informed consent Willing to use adequate contraception Give written informed consent Exclusion Criteria: Primary psychotic or bipolar disorder History of intolerance to statins or presence of any contraindication to statins Presence of any serious medical condition or neurological problem Presence of autoimmune or inflammatory disorder Alcohol or drug dependence Active suicidal ideation Pregnant or breast-feeding.